Evidence map›Paper›PMID 42834163›Full record

ArticleBritish journal of cancer2026

Abundant CD8

Takanari Okamoto, Ryo Mizuta, Ayako Demachi-Okamura, Daisuke Muraoka, Yasunori Fukushima, Hiromasa Ishihara, Yujia Sun, Yizheng Wang, Reina Nishida, Eiichi Sasaki and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Takanari OkamotoDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan. takanari@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0002-4124-180X
Ryo MizutaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Ayako Demachi-OkamuraDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Daisuke MuraokaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yasunori FukushimaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Hiromasa IshiharaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yujia SunDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Yizheng WangDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Reina NishidaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Katsuhiro MasagoDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Kazuhide OnoguchiAI Drug Development Division, NEC Corporation, Minato-ku, Japan.
Yuki TanakaAI Drug Development Division, NEC Corporation, Minato-ku, Japan.
Yoshiko YamashitaAI Drug Development Division, NEC Corporation, Minato-ku, Japan.
Richard StratfordNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Oslo Cancer Cluster, Oslo, Norway.
Osamu MutoDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Chin Leng TanGerman Cancer Research Center (DKFZ) Heidelberg, CCU Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2529-1030
Yoshihiro OtaniDepartment of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Yoshinobu TakahashiDepartment of Neurosurgery, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Rui YamaguchiDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Edward W GreenGerman Cancer Research Center (DKFZ) Heidelberg, CCU Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany.
Michael PlattenGerman Cancer Research Center (DKFZ) Heidelberg, CCU Neuroimmunology and Brain Tumor Immunology, Heidelberg, Germany.
Isao DateDepartment of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Shota TanakaDepartment of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Naoya HashimotoDepartment of Neurosurgery, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Hirokazu MatsushitaDivision of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan. hynymatsu@outlook.jp.ORCID http://orcid.org/0000-0001-9069-7160

Funding

Hori Sciences and Arts Foundation (Hori Sciences & Arts Foundation) N/SUehara Memorial Foundation N/S
6 · The paper itself

Abstract

backgroundThe effectiveness of immunotherapy against glioblastoma (GBM) remains limited, suggesting that antigen-specific tumor-infiltrating lymphocytes (TILs) are rare. This study aimed to identify tumor-specific T cells in GBM as the basis for antigen-specific immunotherapy.

methodsTumor specimens were collected from 56 patients newly diagnosed with IDH-wildtype GBM. In cases showing prominent intratumoral T-cell infiltration, CD3⁺CD8⁺CD4⁻ T cells were sorted for single-cell RNA and T-cell receptor (TCR) sequencing. Integrated analyses were performed using our single-cell dataset from the Aichi Cancer Center (ACC), publicly available GBM TILs datasets (PA), and lung cancer TILs and malignant pleural effusions datasets (LC). Candidate reactive TCRs were identified using an AI-based algorithm.

resultsUnsupervised analysis identified a dominant cluster characterized by the strong expression of exhaustion markers, most prominently LAG3, with high TCR clonality. Moreover, LAG3 and CXCL13 expression levels were significantly higher in the ACC TIL-rich subset than the PA dataset. Finally, a prediction algorithm suggested that our TIL-rich subset harbored a markedly higher proportion of potentially reactive T cells than the PA and LC datasets.

conclusionsTILs with marked clonal expansion in certain GBM cases may include potentially reactive T cells with distinct exhaustion features, providing a foundation for the development of antigen-specific and LAG-3-targeted immunotherapies.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.